Navigation Links
NeoStem Signs Stem Cell Collection Agreement With University of Louisville Hospital

Center to Collect Adult Stem Cells for Storage and to Advance VSEL Research

NEW YORK, May 27 /PRNewswire-FirstCall/ -- NeoStem, Inc. (Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, today announced that it has signed a collection center agreement with the University of Louisville Hospital/ James Graham Brown Cancer Center.

Robin Smith, MD MBA, NeoStem's Chairman and Chief Executive Officer commented: "This is an extraordinary agreement for NeoStem and University of Louisville that will allow us to move adult stem cell therapies forward, both at the basic science and translational level."

NeoStem acquired the exclusive worldwide rights to Very Small Embryonic-Like (VSEL) Stem Cell technology developed by researchers at the University of Louisville in November 2007. VSELs have been identified in adult bone marrow and resemble embryonic stem cells both morphologically and transcriptionally. Although early stage technology, the Company expects VSELS to serve as the basis for its entry into the therapeutic market place. VSELs have the ability to grow in the laboratory and multiply into clusters of cells that then can differentiate into specialized cells found in different types of tissue including cardiac, neural, endothelial, muscle, pancreatic and hematopoietic cells. However, unlike controversial embryonic stem cells, VSELs can be harvested from adult peripheral blood. These naturally occurring regenerative cells may have the potential to be used for future therapeutic repair of degenerative, diseased or damaged tissue.

"The Louisville collection center represents a unique opportunity for University of Louisville," added Manuel Martinez, M.D., Executive Vice President for Research, University of Louisville. "There are a number of adult stem cell translational scientists and clinicians at the University that are interested in exploring the therapeutic potential of VSELs and other adult stem cells of the body. The collection center will allow harvesting large numbers of these cells from adults donating them for basic research as well as clients paying to have their cells stored for their own future medical need."

"By enabling investigators to have access to large numbers of adult stem cells from interested and informed study subjects, we believe that translational adult stem cell research will move forward at an accelerated pace and that clinical trial designs will be more rapidly implemented to investigate new research findings. Overall, we anticipate that this corporate and academic relationship will assist in propelling the adult stem cell field forward. This will allow NeoStem to take the lead in harnessing and translating this revolutionary and promising new approach to treat human disease."

About NeoStem, Inc.

NeoStem has a growing nationwide network of adult stem cell collection centers, enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also recently entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's periodic filings with the Securities and Exchange Commission.


NeoStem, Inc.

Robin Smith, Chief Executive Officer

T: 212-584-4180


SOURCE NeoStem, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pot bellies linked to early signs of cardiovascular disease
2. MSU engineering team designs innovative medical device
3. Jump in Youth Suicide Prompts National Childrens Charity KidsPeace to Issue Tips on Prevention, Warning Signs
4. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
5. Gov. Blagojevich Signs Bill Improving Illinois Mental Illness Treatment Law
6. A new technology for cancer screening listens for the signs of cancer
7. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
8. Pearson VUE Signs Exclusive Contract with Educational Resources, Inc.
9. Former Ronco President Tim Dupler Signs International Direct Sales and Marketing Contract with Natural Nutrition
10. KARL LAGERFELD SAS Signs Global Eyewear License Agreement With Marchon Eyewear, Inc.
11. MIT Holding, Inc. signs partnership agreement with Georgia Southern University
Post Your Comments:
(Date:12/1/2015)... ... ... ClinicoEconomics and Outcomes Research has published the ... ”. , As corresponding author Dr Ankita Modi says “Pre-existing gastrointestinal events may ... a large US managed care database, women aged 55 years or older with ...
(Date:12/1/2015)... ... December 01, 2015 , ... Physicians’ Education Resource®, ... (CME), today announced that the first annual School of Gastrointestinal Oncology™ (SOGO™) will ... detection and treatment of gastrointestinal cancers are undergoing transformational change, providing oncologists with ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Growth in ... part due to decreases in utilization of hospital and nonhospital care, according to a ... CompScope™ Medical Benchmarks for Louisiana, 16th Edition , found medical payments per claim with ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... medical images have been lifted as IMAGE Information Systems launches MED-TAB™ -- the ... North America Annual Meeting from November 29 to December 4, 2015. , ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage ... (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced ... Radiological Society of North America (RSNA) 2015 annual meeting through December 3 in ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015 Breg, Inc ., a premier ... that it has been awarded three contracts by Novation, ... Novation will have access to improved pricing for Breg,s ... soft goods dedicated to advancing orthopedic care.  ... U.S. population, rising prevalence of chronic conditions and the ...
(Date:12/1/2015)... , December 1, 2015 Russia ... III clinical trials. 70% of new drugs registered in Europe ... in Russia . --> Russia has always ... 70% of new drugs registered in Europe in ... --> Russia has always been a ...
(Date:12/1/2015)... 1, 2015 CytRx Corporation (NASDAQ: CYTR ... oncology, today announced that it has reached its enrollment ... Phase 3 clinical trial of aldoxorubicin in patients with ... to be completed in Q1 2016. The Phase 3 trial ... Special Protocol Assessment from the FDA at 79 sites ...
Breaking Medicine Technology: